Recurrent refractory polychondritis: A case report
PDF
Cite
Share
Request
Case Report
P: 82-86
July 2024

Recurrent refractory polychondritis: A case report

J Turk Soc Rheumatol 2024;16(2):82-86
No information available.
No information available
Received Date: 13.12.2023
Accepted Date: 30.05.2024
Online Date: 22.07.2024
Publish Date: 22.07.2024
PDF
Cite
Share
Request

Abstract

Relapsing polychondritis (RP) is an immune-mediated systemic disease characterized by recurrent attacks of inflammation of cartilage and proteoglycan-rich tissues, resulting in progressive anatomical deformation and functional impairment in the affected areas. The most common clinical features include ear and nasal chondritis, as well as polyarthritis, though potentially all cartilage areas can be affected. Delay in diagnosis is frequently encountered due to the progression of the disease and non-specific symptoms at the beginning. 30% of RP patients may have concomitant autoimmune disorders. In our case, a 42-year-old male patient diagnosed with RP was treated with methotrexate, leflunomide, tumor necrosis factor inhibitors and tociluzumab, but showed no improvement. Consequently, the patient was administered cyclophosphamide. Unfortunately, pneumomediastinum developed on the sixth day of treatment. The condition resolved without the need for surgical intervention. However, although the case received many treatments mentioned in the literature, he still did not go into complete remission.

References

1Borgia F, Giuffrida R, Guarneri F, Cannavò SP. Relapsing Polychondritis: An Updated Review. Biomedicines. 2018;6.
2Mertz P, Costedoat-Chalumeau N, Ferrada MA, et al. Relapsing polychondritis: clinical updates and new differential diagnoses. Nat Rev Rheumatol. 2024;20:347-360.
3Zeuner M, Straub RH, Rauh G, Albert ED, Schölmerich J, Lang B. Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients. J Rheumatol. 1997;24:96-101.
4Alsalameh S, Mollenhauer J, Scheuplein F, et al. Preferential cellular and humoral immune reactivities to native and denatured collagen types IX and XI in a patient with fatal relapsing polychondritis. J Rheumatol. 1993;20:1419-24.
5Yang CL, Brinckmann J, Rui HF, et al. Autoantibodies to cartilage collagens in relapsing polychondritis. Arch Dermatol Res. 1993;285:245-9.
6Foidart JM, Abe S, Martin GR, et al. Antibodies to type II collagen in relapsing polychondritis. N Engl J Med. 1978;299:1203-7.
7Trentham DE, Le CH. Relapsing polychondritis. Ann Intern Med. 1998;129:114-22.
8Vounotrypidis P, Sakellariou GT, Zisopoulos D, Berberidis C. Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra). Rheumatology (Oxford). 2006;45:491-2.
9Wendling D, Govindaraju S, Prati C, Toussirot E, Bertolini E. Efficacy of anakinra in a patient with refractory relapsing polychondritis. Joint Bone Spine. 2008;75:622-4.
10Moulis G, Sailler L, Astudillo L, Arlet P. Abatacept for relapsing polychondritis. Rheumatology (Oxford). 2010;49:1019.
11Moulis G, Sailler L, Pugnet G, Astudillo L, Arlet P. Biologics in relapsing polychondritis: a case series. Clin Exp Rheumatol. 2013;31:937-9.
12Ferrada MA, Sikora KA, Luo Y, et al. Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS. Arthritis Rheumatol. 2021;73:1886-95.
13Arnaud L, Costedoat-Chalumeau N, Mathian A, et al. French practical guidelines for the diagnosis and management of relapsing polychondritis. Rev Med Interne. 2023;44:282-94.
14Moulis G, Pugnet G, Costedoat-Chalumeau N, et al. Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study. Ann Rheum Dis. 2018;77:1172-8.
15Handa H, Ooka S, Shimizu J, Suzuki N, Mineshita M. Evaluation of airway involvement and treatment in patients with relapsing polychondritis. Sci Rep. 2023;13:8307.
16Petitdemange A, Sztejkowski C, Damian L, et al. Treatment of relapsing polychondritis: a systematic review. Clin Exp Rheumatol. 2022;40(Suppl 134):81-5.
17Yoshida T, Nishimura K, Murabe H, Yokota T. Dapsone-induced methaemoglobinaemia in relapsing polychondritis. BMJ Case Rep. 2022;15.
18Heiblig M, Ferrada MA, Koster MT, et al. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood. 2022;140:927-31.
19Comont T, Heiblig M, Rivière E, et al. Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. Br J Haematol. 2022;196:969-74.
20Hellmich B, Hering S, Duchna HW, et al. Atemwegsbeteiligung bei Rezidivierender Polychondritis. Zeitschrift für Rheumatologie. 2003;62:73-9.
21Wu S, Sagawa M, Suzuki S, et al. Pulmonary Fibrosis with Intractable Pneumothorax: New Pulmonary Manifestation of Relapsing Polychondritis. Tohoku J Exp Med. 2001;194:191-5.
22Wang S, Jiao Y. Mediastinal emphysema: a rare respiratory complication of relapsing polychondritis. BMJ Case Rep. 2013;2013.
Article is only available in PDF format. Show PDF
2024 ©️ Galenos Publishing House